Delivered November 11, 2020. Contributor: Hanine K.
To get informed about the treatment landscape of nmCRPR, the available treatment options, the treatment decision-making process for healthcare professionals (HCPs), and the motivators to use a treatment over another.
"Prostate cancer is the most common cancer in men, accounting for 19% of new cancer cases." According to the American Cancer Society, in 2019, nearly 174,650 new cases of prostate cancer were diagnosed in the United States, and about 31,620 American men died from prostate cancer.
Not all cases can be cured with localized treatment options. In fact, twenty to thirty percent of men experience "a disease recurrence requiring systemic hormonal treatment with androgen-deprivation therapies (ADTs)."
ADTs are medical or surgical treatments that lower testosterone. These treatments include treatments to "suppress or block the production or action of male hormones called androgens, of which testosterone is the primary androgen. While ADT is often effective, in certain men, prostate cancer adapts and can progress."
Castration-resistant prostate cancer (CRPC), the disease progression despite ADT treatment, is treated with nonmetastatic CRPC (nmCRPC), which works essentially on delaying metastasis while maintaining the patient survival quality.
Traditionally, the main treatment options were first-generation androgen receptor inhibitors (FGARIs) and active surveillance.